Compare WETH & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | COCP |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 14.1M |
| IPO Year | 2020 | 2011 |
| Metric | WETH | COCP |
|---|---|---|
| Price | $1.36 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 161.5K | 56.5K |
| Earning Date | 04-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.38 | ★ 54.65 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $45,136,818.00 | $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.13 | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $0.78 | $0.86 |
| 52 Week High | $3.68 | $2.19 |
| Indicator | WETH | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 36.40 |
| Support Level | $1.30 | $0.91 |
| Resistance Level | $1.48 | $1.09 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 84.06 | 4.71 |
Wetouch Technology Inc is a business of research and development, manufacturing, and distribution of touchscreen displays to customers both in the PRC and overseas. The touchscreen products, which are manufactured by the Company, are mainly for use in financial terminals, automotive, Point of Sales, gaming, lottery, medical, Human-Machine Interface (HMI), and other specialized industries. The company sells touchscreen products both domestically in China and internationally, covering areas in Mainland China, including but not limited to the eastern, southern, northern, and southwest regions of Mainland China, Taiwan, South Korea, Germany, and other countries.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.